Or the publisher’s dilemma how to present a growing complexity of scientific knowledge to clinicians, helping them to improve their daily care for their patients
Authors:
Wolfgang Hilbe, MD, Rupert Bartsch, MD, Waltraud Radlherr
Ten years ago, in spring 2007 a noble lady wearing a queenly looking hat invited me (WH) to start a new printed journal on hematology and oncology with a focus on the German-speaking community. The well-known publisher Springer Company intended to expand in that field of medicine. Certainly, it was a distinguished honor being selected for such a project. But, analyzing the opportunities and potential draw-backs of such a project, I came to the conclusion: “hands off!”. Considering the small number of Austrian hematologists and medical oncologists, the potential of authors or reviewers would have been fully exhausted within the first three issues.
To print or not to print Or the publisher’s dilemma how to present a growing complexity of scientific knowledge to clinicians, helping them to improve their daily care for their patients
Authors
Wolfgang Hilbe, MD Rupert Bartsch, MD Waltraud Radlherr
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.